Skip to main content
Signal8

GeneDx Holdings Corp. (WGS) Form 8-K — Nov 18, 2026

$WGSForm 8-KItems 5.02, 7.01, 9.01Filed Nov 18, 2026, 8:16 AM ET0001104659-26-129358Original filing

GeneDx (Nasdaq: WGS) announced that CEO Katherine Stueland will step down and resign from the Board when Everett Cunningham takes over as CEO, effective on or before December 15, 2026. Stueland will stay as an Executive Advisor through January 31, 2027, with her March 2027 RSU vesting accelerated in lieu of salary severance. Cunningham, most recently CEO of Quanterix, brings more than 35 years of diagnostics and commercial leadership experience from Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics and Pfizer. He receives a $750,000 base salary, a $1,050,000 sign-on bonus, and $10.0 million each in time-based RSUs and price-hurdle PRSUs.

Key figures

Sign on bonus
$1,050,000
Transition date
on or before December 15, 2026
Stueland exit date
January 31, 2027
New ceo base salary
$750,000
Initial rsu award value
$10.0 million
Initial prsu award value
$10.0 million
Target bonus pct of base
100%
Annual refresh prsu target value
$4,000,000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.